Breaking the Wall between Commercial and Medical Affairs – How Leading Pharmas are Delivering Sustainable, Cost Effective & Consistent Training Across Unique Audiences: An Expert Panel

  • Philip Bedrin, ScienceMedia, Inc.,
  • Doug Kennett, Amgen,
  • Valerie Levi, Daiichi Sankyo,
  • Tara K. Leahy, Daiichi Sankyo,
  • Laura Last, Amgen,
  • Michael W. Young, ScienceMedia Inc.

CASE STUDY: Within large biopharma organizations, there are huge duplications of effort and significant overlap of spend. This also occurs within the sales and medical affairs training initiatives. This common practice in larger organizations is also an environment in which consistency and quality of training, currency and accuracy of training, as well as global sustainability of training platforms can be called into question.

AMGEN Pharmaceuticals has recently sought to break down the wall between medical affairs training and commercial training; acknowledging the distinct regulatory treatment differences, but seeking common ground on training content and delivery to create significant efficiencies and improvements in cost, quality, consistency, and delivery.

This case study discussion will enable the attendee to evaluate their own internal needs and capabilities within their own organization and seek to apply similar considerations and criteria potentially leading to higher efficiency and more effective training platforms which can leverage common content and technology while meeting the needs and complexity of contemporary sales and medical affairs teams.

  • Date:Wednesday, June 5
  • Time:8:30 AM - 9:30 AM
  • Room:Austin 4
  • Location:Austin 4
  • Session Type:Thought Leader Panel
  • Submitter Name: Young, Michael
  • Submission Date (CST): 09/01/2019 23:11
  • Session Level: Intermediate
  • Submitter Email:
  • Session Length: 60 Minute Workshop
  • How are you planning on keeping the learners engaged during this presentation?: The workshop will be didactic presentation but will also involve an active description of common issues by the attendee audience.
  • Learning Objective 1: What circumstances led to looking for greater efficiencies, cost savings, and consistency in training across the enterprise.
  • Learning Objective 2: How and what stakeholders did Amgen engage to allow this change to occur?What things do you need to consider?What actions make this successful?
  • Learning Objective 3: How will Amgen know this is a good investment?How will they work with the supplier to ensure success?What metrics will be used?
  • What is the topic your workshop will cover and how is it relevant to the industry?: To help attendees understand why and how a Top 5 biopharma company saw ways to break down the wall between Commercial and Medical Affairs training
Philip Bedrin
ScienceMedia, Inc.
Doug Kennett, Amgen
Valerie Levi, Daiichi Sankyo
Tara K. Leahy, Daiichi Sankyo
Laura Last, Amgen
Michael W. Young
ScienceMedia Inc.